ASP Isotopes (NASDAQ:ASPI) COO Sells $59,066.00 in Stock

ASP Isotopes Inc. (NASDAQ:ASPI) COO Robert Ainscow sold 8,438 shares of the company’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $7.00, for a total transaction of $59,066.00. Following the transaction, the chief operating officer owned 2,281,879 shares in the company, valued at $15,973,153. This represents a 0.37% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Robert Ainscow also recently made the following trade(s):

• On Thursday, April 16th, Robert Ainscow sold 22,500 shares of ASP Isotopes stock. The shares were sold at an average price of $5.21, for a total transaction of $117,225.00.

ASP Isotopes Price Performance

Shares of NASDAQ ASPI opened at $6.55 on Friday. The firm’s 50-day moving average price is $5.74 and its 200-day moving average price is $5.85. ASP Isotopes Inc. has a 1-year low of $3.92 and a 1-year high of $14.49. The firm has a market capitalization of $824.65 million, a P/E ratio of -3.15 and a beta of 3.42. The company has a current ratio of 4.39, a quick ratio of 4.37 and a debt-to-equity ratio of 0.69.

ASP Isotopes (NASDAQ:ASPI) last announced its quarterly earnings data on Wednesday, May 20th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.06. ASP Isotopes had a negative net margin of 644.40% and a negative return on equity of 112.46%. The firm had revenue of $8.36 million for the quarter, compared to analyst estimates of $3.68 million.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on ASPI. Weiss Ratings restated a “sell (d-)” rating on shares of ASP Isotopes in a report on Friday, March 27th. Canaccord Genuity Group restated a “buy” rating and issued a $11.00 target price on shares of ASP Isotopes in a report on Tuesday, April 14th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, ASP Isotopes currently has an average rating of “Hold” and an average price target of $13.00.

Institutional Investors Weigh In On ASP Isotopes

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quantbot Technologies LP purchased a new stake in ASP Isotopes in the 3rd quarter valued at about $34,000. BNP Paribas Financial Markets increased its stake in ASP Isotopes by 84.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock valued at $41,000 after buying an additional 2,548 shares during the last quarter. State of Wyoming purchased a new stake in ASP Isotopes in the 1st quarter valued at about $29,000. Close Asset Management Ltd purchased a new stake in ASP Isotopes in the 3rd quarter valued at about $72,000. Finally, Legal & General Group Plc increased its stake in ASP Isotopes by 30.4% in the 3rd quarter. Legal & General Group Plc now owns 8,377 shares of the company’s stock valued at $81,000 after buying an additional 1,953 shares during the last quarter. Hedge funds and other institutional investors own 16.80% of the company’s stock.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.